Early-phase trial data for a theranostic radiopharmaceutical, 177Lu-NeoB, demonstrate safety and potential tumour control in patients with GRPR-positive …
Early-phase trial data for a theranostic radiopharmaceutical, 177Lu-NeoB, demonstrate safety and potential tumour control in patients with GRPR-positive …
Phase III SEQUOIA-HCM analyses show aficamten offers benefit to patients with varying symptom severity and across regions, opening …
In May 2025, a gene therapy for Rett syndrome has cleared major regulatory design review and is activating …
New oral vaccine succeeds against multiple cholera strains offering promise for broad use in endemic regions
New antibody therapeutic enters Phase 1 with hopes of helping women with hot flashes and night sweats
Mid-stage results show meaningful reductions in pathological protein, setting stage for later-phase trials
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
TRANQUILITY trial results strengthen case for pacibekitug as a potential quarterly IL-6 inhibitor for cardiovascular inflammation in chronic …
Dual clinical studies reveal statistically meaningful benefits for patients with MSA, highlighting a leap forward for disease-modifying treatment …
Phase III ASCENT-04/KEYNOTE-D19 trial reveals meaningful PFS improvement with a novel antibody-drug conjugate/immunotherapy combo
Already a subscriber? Log in